Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

Spontaneous remission of fully symptomatic visceral leishmaniasis

  • 1Email author,
  • 5,
  • 2,
  • 1,
  • 4,
  • 1, 6,
  • 2,
  • 3 and
  • 1, 6
Contributed equally
BMC Infectious Diseases201515:445

https://doi.org/10.1186/s12879-015-1191-6

  • Received: 14 April 2015
  • Accepted: 7 October 2015
  • Published:
Open Peer Review reports

Abstract

Background

Visceral leishmaniasis (VL), i.e., infection with Leishmania sp. associated with high fever, weight loss, massive splenomegaly and markedly altered laboratory parameters, is generally fatal if untreated. The possibility of transient spontaneous remission of fully symptomatic visceral leishmaniasis (VL) has been mentioned but, to our knowledge) has never been documented.

Case presentation

We report the first documented history of a patient with overt, confirmed VL experiencing a complete remission in the absence of any anti-leishmanial therapy. The diagnosis of VL at the time of the self-resolving episode was strongly suspected based on clinical presentation and presence of antileishmanial antibody, then unequivocally confirmed years later by the presence of an amastigote on a stored smear and the positive quantitative PCR with Leishmania-specific primers from the material scraped from this same slide

Conclusion

This report demonstrates that complete spontaneous remission may occur in patients with overt, fully symptomatic VL. VL should therefore be considered in cases of self-resolving or relapsing episodes of fever of unknown origin. Confirmation should be based on both serological tests and specific PCR on a blood sample.

Keywords

  • Visceral leishmaniasis
  • Spontaneous remission
  • Hemophagocytic lymphohistiocytosis
  • Real time PCR
  • Giemsa stained
  • Bone marrow smear

Background

Overt visceral leishmaniasis, i.e., infection with Leishmania sp. associated with high fever, weight loss, massive splenomegaly and markedly altered laboratory parameters, is generally considered fatal if untreated [1, 2]. The possibility of transient spontaneous remission has been mentioned [3] but, to our knowledge, has never been precisely documented because patients with documented VL are treated. We provide the first description of a complete, prolonged remission of fully symptomatic VL in a patient who had not received any anti-leishmanial therapy.

Case presentation

In July 2008, a 27-year-old immunocompetent male patient was referred to our hospital for a 3-week history of fever, asthenia and pancytopenia. The patient had spent 4 month in an area endemic for Leishmania infantum in the South of France (Oriental Pyrennees). His medical history included dental infections and an allergy to methicillin. He reported two similar episodes of high fever and asthenia in 2006 (Table 1). The first episode in June 2006 had resolved spontaneously. During the second episode, in November, the patient was hospitalized with splenomegaly (17 cm), fever (40 °C) and weight loss (10 kg), anemia, leucopenia and thrombocytopenia (Table 1). Microscopic examination of a bone marrow (BM) aspirate was negative for parasites. The bone marrow smear showed normal cellularity and there was no indication of immunosuppression. All microbiological and immunological tests were negative (blood and urine culture, testing for HIV, salmonella, brucellosis, Lyme borreliosis, hepatitis A, cytomegalovirus infection, arboviral infection, and malaria) except for positive titers of anti-Leishmania antibody (IFA 1/400) and a positive serology for EBV suggestive of prior infection. In this context of fever of unknown origin, a presumptive 8-day course of intravenous antibiotic therapy (ceftriaxone and ofloxacin) was administered. All signs and symptoms, including fever, splenomegaly and asthenia, resolved in 4 weeks. No specific anti-leishmanial drug had been administered, as the treating physician had not retained this diagnosis. All laboratory parameters normalized during the same period, confirming complete remission of the episode (Table 1).
Table 1

 

2006 Nov. 13th

2007, Feb. 1st

2008, July 2nd

2008, July 11th

2008, July 21st

2009, Jan. 15th

Antileishmanial agent

   

L-AmB Day1

L-AmB Day10

 

Antimicrobial agents

Ciprofloxacin ceftriaxone

     

Clinical parameters

      

Temperature (°C)

40

37

40

38.2

36.1

36.5

Weight (kg)

59

73

68

  

72

Biological parameters

      

White blood cell count (/mL)

1.480

7.000

1.280

0.990

4.110

9.200

Neutrophils (/mL)

0.720

4.018

0.563

0.495

1.993

6.522

Lymphocytes (/mL)

0.650

2.065

0.640

0.455

1.780

1.536

Hemoglobin (g/dL)

9.6

14.8

9.9

9.1

11.6

16.2

Platelet count (/mL)

87.000

197.000

75.000

64.000

250.000

182.000

ASAT (IU/L)

126

21

51

93

 

20

ALAT (IU/L)

56

18

15

19

 

17

C-reactive protein (mg/L)

160

1.9

63

97

4

 

Ferritin (μg/L)

19.295

57

2.093

   

Fibrinogen (g/l)

2.5

3.5

3.5

   

Triglycerides (mmol/L)

2.32

 

2.21

   

LDH (IU/L)

1.400

250

1.010

   

In 2008, relapse occurred with weight loss (4 kg), fever (40 °C) and arthralgia (Table 1). Physical examination showed an enlarged spleen, measuring 20 cm on the subsequent CT scan. Antinuclear antibodies were positive (dilution of 1/1280) with a nonspecific pattern. The bone marrow (BM) aspirate showed hemophagocytosis. All microbiological tests, including Histoplasma capsulatum antibody were negative except anti-leishmanial antibody titers that were again positive (ELISA >1.7 for a threshold at 1). Quantitative polymerase chain reaction (PCR) on a L. infantum kinetoplast DNA target found 30 parasites per mL, i.e., above the threshold for active VL (1 parasite/ml) [4]. Blood and BM cultures for L. infantum were negative.

Fever lasted 4 weeks before the diagnosis of VL was confirmed. The patient was then treated with liposomal Amphotericin B (l-AmB) (3 mg/kg/day D1-5 and D10) [5]. Complete fever resolution was obtained in 3 days along with a dramatic improvement of the patient’s general well-being. Ultrasonography showed regression of splenomegaly from 20 to 14 cm at the end of the first week, followed by normalization to 12 cm 6 months later. At that time laboratory parameters had returned to normal levels (Table 1) and quantitative PCR for L. infantum was negative. When last seen, in September 2010, the patient was completely asymptomatic.

We reexamined a bone marrow smear performed in 2006 during the first hospitalization. Independent, complete examination of this smear by 2 observers (10 h of observation under the microscope) revealed the presence of a single typical amastigote form of Leishmania sp. (Fig. 1). Material on the smear was then thoroughly scarped from the slide with a blade and resuspended in 30 μl of sterile distilled water. Real time PCR amplification was performed in a thermal cycler TAQMAN® (Applied Biosystems) using Leishmania kDNA specific primers as described by Mary et al. [4]. One negative blood slide and one negative tissue slide were used as controls. Amplification of the material retrieved from the slide occurred at 28 CTs, corresponding to the presence of 1.8 parasites (Fig. 1).
Fig 1
Fig 1

Amplification profile in RT-PCR of the Giemsa slide of the bone marrow smear, the negative blood slide and the negative tissue slide, the amplification of the Leishmania kinetoplast DNA is labeled in orange and the amplification of the DNA of the Internal Positive Control (IPC) is labeled in Grey. The amplification of the kinetoplast DNA of Leishmania from the Giemsa slide of the bone marrow smear is indicated by red vertical dotted line and occurred at 28 CTs which corresponds to the presence of 1.8 parasites on the slide. The amplification of the kinetoplast DNA of Leishmania from the five positive points of the range are indicated by blue vertical dotted lines. Typical amastigote form of Leishmania sp (2–3 mm in diameter) seen in smear bone marrow shown in insert squares at the left side of the figure. The nucleus and kinetoplast are in red arrow. Staining May Grunwald Giemsa (MGG) x1000. *Parasite

Discussion

This is the first documented report of a patient with overt, confirmed VL experiencing a complete remission in the absence of any anti-leishmanial therapy. The diagnosis of VL at the time of the self-resolving episode was strongly suspected based on clinical presentation and presence of antileishmanial antibody, then unequivocally confirmed years later by the presence of an amastigote on a stored smear. Quantitative PCR from the material scraped from this same slide using Leishmania-specific primers was positive. The excellent specificity of this PCR has been confirmed by several teams [4, 69]. The last episode, during which PCR was positive in a blood sample was followed by a positive outcome under anti-leishmanial therapy with liposomal amphotericin B. No relapse occurred during the 2 years following administration of anti-leishmanial therapy, which is consistent with the high efficacy of l-AmB in Mediterranean VL [10].

It has been known for decades that patients with mild symptoms of VL may recover spontaneously and that a minority eventually develop overt clinical VL [11]. In L. infantum transmission foci, asymptomatic infections and mild clinical forms of VL are indeed frequent in humans [12, 13]. This is different from the spontaneous remission of fully symptomatic severe VL, as described here. Uncontrolled studies that show improvement or apparent cure in patients receiving experimental anti-leishmanial interventions for overt VL should thus be interpreted cautiously [14, 15]. We cannot definitely exclude the hypothesis that the short course of intravenous antibiotic therapy (ceftriaxone and ofloxacin during 8 days) during the first episode may have contributed to the patient's improvement. A few reports in vitro or in animals suggest indeed that quinolones may have some activity against Leishmania [1618] thus possibly contributing to the control of parasite loads. Thereafter, the patient was appropriately treated and cured with liposomal Amphotericin B.

For confirmation of VL, PCR in the blood is more sensitive than conventional search of the parasite even in bone marrow aspirates. Time spent for reading Giemsa-stained smears in the search for Leishmania amastigotes increases the test sensitivity that raises to 95.4 % after 60 min and 89.7 % when 1.200 fields are examined [19]. When a macrophage activation syndrome is present, repetition of bone marrow aspirates also increases diagnostic sensitivity [20]. Why patients would spontaneously recover from overt VL is not clear. Interestingly, our patient met five out of the eight criteria of the hemophagocytic lymphohistiocytosis (HLH-2004 revised diagnostic guidelines) [21]. Therefore, if HLH had also occurred during the initial episode, phagocytosis of Leishmania-infected cells by previously activated macrophages, or a general activation of macrophages as observed in HLH, may have contributed to the control of parasite loads. This hypothesis is consistent with the absence of Leishmania amastigotes in bone marrow aspirates in 36.3 % of patients with VL and HLH [22].

Conclusion

In summary, this report demonstrates that complete spontaneous remission may occur in patients with overt, fully symptomatic VL. VL should therefore be considered in cases of self-resolving or relapsing episodes of fever of unknown origin. Confirmation should be based on both serological tests and specific PCR on a blood sample.

Consent

Notes

Abbreviations

VL: 

Visceral leishmaniasis

PCR: 

Polymerase chain reaction

HIV: 

Human immunodeficiency virus

EBV: 

Epstein-barr virus

HLH: 

Hemophagocytic lymphohistiocytosis

Declarations

Acknowledgements

We thank nurses and technicians from the medical department and the clinical laboratory for their outstanding contribution to the management of patient. This work was not supported by any external funding.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
AP-HP, Hôpital Pitié-Salpêtrière, Service de Parasitologie, F-75013 Paris, France
(2)
AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, F-75013 Paris, France
(3)
AP-HP, Hôpital Cochin, Service de Médecine Interne. Centre de référence maladies auto-immunes et systémiques rares, Service de Médecine Interne, F-75014 Paris, France
(4)
Hopital Sud Francilien, Service d’Hématologie, Corbeil-Essonnes, France
(5)
AP-HP, Hôpital Cochin, Service de Rééducation et Réadaptation, F-75014 Paris, France
(6)
UPMC Université Paris 06, Centre Immunologie et Maladies Infectieuses, F-75005 Paris, France

References

  1. Pearson R, de Queiroz Sousa A, Jeronimo SB. Leishmania species: visceral (Kala-Azar), cutaneous and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. Volume 2. Philadelphia: Churchill Linvingstone; 2000. p. 2831–45.Google Scholar
  2. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs. 2009;14(3):395–410.View ArticleGoogle Scholar
  3. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008;2(10), e313.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol. 2004;42(11):5249–55.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996;22(6):938–43.View ArticlePubMedGoogle Scholar
  6. Brustoloni YM, Lima RB, da Cunha RV, Dorval ME, Oshiro ET, de Oliveira AL, et al. Sensitivity and specificity of polymerase chain reaction in Giemsa-stained slides for diagnosis of visceral leishmaniasis in children. Mem Inst Oswaldo Cruz. 2007;102(4):497–500.View ArticlePubMedGoogle Scholar
  7. Fisa R, Riera C, Lopez-Chejade P, Molina I, Gallego M, Falco V, et al. Leishmania infantum DNA detection in urine from patients with visceral leishmaniasis and after treatment control. Am J Trop Med Hyg. 2008;78(5):741–4.PubMedGoogle Scholar
  8. Ozerdem D, Eroglu F, Genc A, Demirkazik M, Koltas IS. Comparison of microscopic examination, rK39, and PCR for visceral leishmaniasis diagnosis in Turkey. Parasitol Res. 2009;106(1):197–200.View ArticlePubMedGoogle Scholar
  9. Fraga TL, Brustoloni YM, Lima RB, Dorval ME, Oshiro ET, Oliveira J, et al. Polymerase chain reaction of peripheral blood as a tool for the diagnosis of visceral leishmaniasis in children. Mem Inst Oswaldo Cruz. 2010;105(3):310–3.View ArticlePubMedGoogle Scholar
  10. Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health. 2008;13(10):1272–6.View ArticlePubMedGoogle Scholar
  11. Evans TG, Teixeira MJ, Sousa Ade Q, Pearson RD. Short report: extended follow-up of the natural history of persons infected with Leishmania chagasi. Am J Trop Med Hyg. 1995;53(4):360–1.PubMedGoogle Scholar
  12. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154(6):1003–11.View ArticlePubMedGoogle Scholar
  13. Jeronimo SM, Teixeira MJ, Sousa A, Thielking P, Pearson RD, Evans TG. Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin Infect Dis. 2000;30(3):608–9.View ArticlePubMedGoogle Scholar
  14. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg. 1983;77(2):167–70.View ArticlePubMedGoogle Scholar
  15. Sundar S, Murray HW. Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. J Assoc Physicians India. 1995;43(5):348–50.PubMedGoogle Scholar
  16. Romero IC, Saravia NG, Walker J. Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro. J Parasitol. 2005;91(6):1474–9.View ArticlePubMedGoogle Scholar
  17. Bianciardi P, Fasanella A, Foglia Manzillo V, Trotta T, Pagano A, Sorino S, et al. The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol Res. 2004;93(6):486–92.View ArticlePubMedGoogle Scholar
  18. Cortazar TM, Coombs GH, Walker J. Leishmania panamensis: comparative inhibition of nuclear DNA topoisomerase II enzymes from promastigotes and human macrophages reveals anti-parasite selectivity of fluoroquinolones, flavonoids and pentamidine. Exp Parasitol. 2007;116(4):475–82.View ArticlePubMedGoogle Scholar
  19. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005;72(6):811–4.PubMedGoogle Scholar
  20. Gagnaire MH, Galambrun C, Stephan JL. Hemophagocytic syndrome: A misleading complication of visceral leishmaniasis in children--a series of 12 cases. Pediatrics. 2000;106(4), E58.View ArticlePubMedGoogle Scholar
  21. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.View ArticlePubMedGoogle Scholar
  22. Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review. J Infect. 2008;56(5):381–8.View ArticlePubMedGoogle Scholar

Copyright

© Mouri et al. 2015

Advertisement